Case Report: A rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer
The PD-1 inhibitor sintilimab has been approved for the treatment of various malignancies. Here, we reported a rare case of sintilimab-induced dermatomyositis in a patient with gastric cancer and liver metastasis to raise awareness of this serious adverse event. A 64-year-old man presented with the...
Saved in:
| Main Authors: | Peipei Mou, Fanghua Li, Yingying Wang, Feifei Zhao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1517391/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sintilimab-induced intestinal obstruction and hemorrhage of the digestive tract: a case report
by: Qian Hao, et al.
Published: (2025-07-01) -
Subacute cutaneous lupus erythematosus triggered by sintilimab: a case report
by: Chenxi Zhang, et al.
Published: (2025-04-01) -
Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report
by: Ming-xing Wang, et al.
Published: (2025-01-01) -
Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis/cystitis treated by ureteral stent and review of the literature
by: Jiaxiang Ji, et al.
Published: (2024-12-01) -
Use of sintilimab in primary adenosquamous carcinoma of the liver results in pathological complete response: a case report and literature review
by: Zhiqing Bai, et al.
Published: (2025-04-01)